Admetsys' FDA Breakthrough Designation Accelerates Arrival of Fully Autonomous Clinical Robotics in Hospital
Posted:
Admetsys Corporation, a biomedical technology company specializing in critical care automation, announced today that the FDA has designated its automated glucose control and continuous blood diagnostics system a Breakthrough Device.
Schizophrenia is a psychiatric disorder characterized by altered thinking and emotional patterns, hallucinations, false or irrational beliefs (i.e., delusions), cognitive deficits, and disorganized speech.
Bipolar disorder BD, on the other hand, is marked by extreme mood swings, ranging between periods of…
New joint research program combines UCSF’s advanced clinical and research teams with GE HealthCare’s technical and engineering expertise to develop solutions that directly impact patient care.
Read full article here.
Attendees
Sponsors and Exhibitors
Contact us